Literature DB >> 24913145

A highly recurrent RPS27 5'UTR mutation in melanoma.

Ken Dutton-Regester1, Jared J Gartner2, Rafi Emmanuel, Nouar Qutob, Michael A Davies, Jeffrey E Gershenwald, William Robinson, Steven Robinson, Steven A Rosenberg, Richard A Scolyer, Graham J Mann, John F Thompson, Nicholas K Hayward, Yardena Samuels3.   

Abstract

The incidence of melanoma continues to rise globally and is increasing at a rate greater than any other cancer. To systematically search for new genes involved in melanomagenesis, we collated exome sequencing data from independent melanoma cohort datasets, including those in the public domain. We identified recurrent mutations that may drive melanoma growth, survival or metastasis, and which may hold promise for the design of novel therapies to treat melanoma. These included a frequent recurrent (i.e. hotspot) mutation in the 5' untranslated region of RPS27 in ~10% of samples. We show that the mutation expands the 5'TOP element, a motif known to regulate the expression of most of the ribosomal protein family, to which RPS27 belongs, and thus might sensitize the mutated transcript to growth-mediated regulation. This finding highlights not only the important role of non-protein coding genetic aberrations in cancer development but also their potential as novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913145      PMCID: PMC4102779          DOI: 10.18632/oncotarget.2048

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  38 in total

Review 1.  Synthesis of the translational apparatus is regulated at the translational level.

Authors:  O Meyuhas
Journal:  Eur J Biochem       Date:  2000-11

Review 2.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.

Authors:  R S Kerbel
Journal:  Bioessays       Date:  1991-01       Impact factor: 4.345

3.  Oligopyrimidine tract at the 5' end of mammalian ribosomal protein mRNAs is required for their translational control.

Authors:  S Levy; D Avni; N Hariharan; R P Perry; O Meyuhas
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 4.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

5.  The 5' terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type- and sequence context-dependent manner.

Authors:  D Avni; Y Biberman; O Meyuhas
Journal:  Nucleic Acids Res       Date:  1997-03-01       Impact factor: 16.971

6.  Phase I study of recombinant human endostatin in patients with advanced solid tumors.

Authors:  Roy S Herbst; Kenneth R Hess; Hai T Tran; Jennifer E Tseng; Nizar A Mullani; Chusilp Charnsangavej; Timothy Madden; Darren W Davis; David J McConkey; Michael S O'Reilly; Lee M Ellis; James Pluda; Waun K Hong; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

7.  A growth factor-inducible gene encodes a novel nuclear protein with zinc finger structure.

Authors:  J A Fernandez-Pol; D J Klos; P D Hamilton
Journal:  J Biol Chem       Date:  1993-10-05       Impact factor: 5.157

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 9.  Targeting mTOR signaling for cancer therapy.

Authors:  Shile Huang; Peter J Houghton
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

10.  Whole genome sequencing of matched primary and metastatic acral melanomas.

Authors:  Samra Turajlic; Simon J Furney; Maryou B Lambros; Costas Mitsopoulos; Iwanka Kozarewa; Felipe C Geyer; Alan Mackay; Jarle Hakas; Marketa Zvelebil; Christopher J Lord; Alan Ashworth; Meirion Thomas; Gordon Stamp; James Larkin; Jorge S Reis-Filho; Richard Marais
Journal:  Genome Res       Date:  2011-12-19       Impact factor: 9.043

View more
  25 in total

1.  Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.

Authors:  Gabriela Marsavela; Anna Reid; Elin S Gray; Leslie Calapre
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Acquired ribosomopathies in leukemia and solid tumors.

Authors:  Adrianna Vlachos
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  SDHD Promoter Mutations Ablate GABP Transcription Factor Binding in Melanoma.

Authors:  Tongwu Zhang; Mai Xu; Matthew M Makowski; Christine Lee; Michael Kovacs; Jun Fang; Esther Willems; Jeffrey M Trent; Nicholas K Hayward; Michiel Vermeulen; Kevin M Brown
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

4.  Genomic sites hypersensitive to ultraviolet radiation.

Authors:  Sanjay Premi; Lynn Han; Sameet Mehta; James Knight; Dejian Zhao; Meg A Palmatier; Karl Kornacker; Douglas E Brash
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-13       Impact factor: 11.205

5.  Whole-genome landscapes of major melanoma subtypes.

Authors:  Nicholas K Hayward; James S Wilmott; Nicola Waddell; Peter A Johansson; Matthew A Field; Katia Nones; Ann-Marie Patch; Hojabr Kakavand; Ludmil B Alexandrov; Hazel Burke; Valerie Jakrot; Stephen Kazakoff; Oliver Holmes; Conrad Leonard; Radhakrishnan Sabarinathan; Loris Mularoni; Scott Wood; Qinying Xu; Nick Waddell; Varsha Tembe; Gulietta M Pupo; Ricardo De Paoli-Iseppi; Ricardo E Vilain; Ping Shang; Loretta M S Lau; Rebecca A Dagg; Sarah-Jane Schramm; Antonia Pritchard; Ken Dutton-Regester; Felicity Newell; Anna Fitzgerald; Catherine A Shang; Sean M Grimmond; Hilda A Pickett; Jean Y Yang; Jonathan R Stretch; Andreas Behren; Richard F Kefford; Peter Hersey; Georgina V Long; Jonathan Cebon; Mark Shackleton; Andrew J Spillane; Robyn P M Saw; Núria López-Bigas; John V Pearson; John F Thompson; Richard A Scolyer; Graham J Mann
Journal:  Nature       Date:  2017-05-03       Impact factor: 49.962

6.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

Review 7.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 8.  The functional relevance of somatic synonymous mutations in melanoma and other cancers.

Authors:  Valer Gotea; Jared J Gartner; Nouar Qutob; Laura Elnitski; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 9.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

10.  Functional 5' UTR motif discovery with LESMoN: Local Enrichment of Sequence Motifs in biological Networks.

Authors:  Mathieu Lavallée-Adam; Philippe Cloutier; Benoit Coulombe; Mathieu Blanchette
Journal:  Nucleic Acids Res       Date:  2017-10-13       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.